异动解读 | Summit Therapeutics盘中大涨5.42%,花旗维持买入评级及ASCO数据预期提振反弹

异动解读
May 04

Summit Therapeutics (SMMT) 今日盘中股价大幅上涨5.42%,引起了市场的广泛关注。

消息面上,尽管公司此前因HARMONi-3鳞状非小细胞肺癌中期PFS数据未达统计学显著性而股价受挫,但花旗分析师Yigal Nochomovitz在利空公布后仍维持买入评级及40美元目标价,为市场注入了信心。

此外,公司与康方生物合作的依沃西单抗即将在ASCO会议上公布HARMONi-6总生存期数据,市场对后续催化事件存在期待,共同推动了此次超跌反弹。公司表示HARMONi-3最终PFS结果将于下半年发布。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10